A Phase 1, Open-label Study to Evaluate the Pharmacokinetics and Safety of Multiple Doses of VX-548 in Subjects With Mild or Moderate Hepatic Impairment and in Matched Healthy Subjects
Latest Information Update: 22 Mar 2024
At a glance
- Drugs Suzetrigine (Primary)
- Indications Acute pain; Neuropathic pain; Pain
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
- 22 Aug 2023 Status changed from active, no longer recruiting to completed.
- 29 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Aug 2023.
- 29 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 Aug 2023.